Phytochemical Analysis and *in vitro* Antiviral Activities of the Essential Oils of Seven Lebanon Species

by Monica R. Loizzo*), Antoine M. Saabb), Rosa Tundis*a), Giancarlo A. Statti*a), Francesco Menichini*a), Ilaria Lampronti*a), Roberto Gambarid), Jindrich Cinatle), and Hans Wilhelm Doerr*e)

a) Department of Pharmaceutical Sciences, Faculty of Pharmacy and Health Sciences and Nutrition, University of Calabria, I-87036 Rende (CS) (phone: +39-0984-493169; fax: +39-0984493298; e-mail: mr.loizzo@unical.it)
b) Chemistry Department, Faculty of Sciences II, Lebanese University, P. O.Box: 90656 Fanar, Beirut, Lebanon
c) Biotechnology Centre, University of Ferrara, I-44100 Ferrara
d) ER-GenTech, Department of Biochemistry and Molecular Biology, University of Ferrara, I-44100 Ferrara
e) Institute for Medical Virology, University Hospital of the Johann Wolfgang Goethe University Frankfurt, Paul-Ehrlich-Str. 40, D-60596 Frankfurt

The chemical composition of the essential oils of *Laurus nobilis*, *Juniperus oxycedrus* ssp. *oxycedrus*, *Thuja orientalis*, *Cupressus sempervirens* ssp. *pyramidalis*, *Pistacia palaestina*, *Salvia officinalis*, and *Satureja thymbra* was determined by GC/MS analysis. Essential oils have been evaluated for their inhibitory activity against SARS-CoV and HSV-1 replication *in vitro* by visually scoring of the virus-induced cytopathogenic effect post-infection. *L. nobilis* oil exerted an interesting activity against SARS-CoV with an IC*50* value of 120 mg/ml and a selectivity index (SI) of 4.16. This oil was characterized by the presence of β-ocimene, 1,8-cineole, α-pinene, and β-pinene as the main constituents. *J. oxycedrus* ssp. *oxycedrus* oil, in which α-pinene and β-myrcene were the major constituents, revealed antiviral activity against HSV-1 with an IC*50* value of 200 μg/ml and a SI of 5.

**Introduction.** – In the past decades, besides a variety of synthetic antiviral drugs with different molecular targets, a large number of phytochemicals have been recognized to control infections caused by viruses. Recently, the anti-herpesvirus activity of several essential oils of different plant sources as well as of various constituents of essential oils was demonstrated [1][2].

The severe acute respiratory syndrome (SARS) is a febrile respiratory illness primarily transmitted by respiratory droplets or close personal contact. The causative organism has been identified as a novel coronavirus, *i.e.*, SARS-CoV [3]. The overriding clinical feature of SARS is the rapidity with which many patients develop symptoms of acute respiratory distress syndrome (ARDS). Currently, there are no approved or universally recommended therapies for SARS. Treatment for the disease is mainly supportive.

*Herpes simplex* virus type 1 (HSV-1) is a common human pathogen that causes localized skin infections of the mucosal epithelia of the oral cavity, the pharynx, the oesophagus, and the eyes. The virus may establish an acute primary infection, followed by the development of a latent, lifelong infection [4]. Presently, the only aspect of the
HSV life-cycle for which antiviral therapy has been successfully developed is the process of DNA replication, which is targeted by a small group of nucleoside analogues that include acyclovir (ACV), valaciclovir, and famciclovir. However, ACV-resistant strains of HSV and drug toxicity have been recently reported [5].

*Laurus nobilis* L. was used as folk remedies in different countries to treat numerous diseases. Laurel essential oil was reported to be used in the preparation of hair lotion for its antidandruff activity and for the external treatment of psoriasis [6]. *Thuja orientalis* L. tree was used in various herbal remedies and aromatherapy preparation. In traditional Chinese medicine, the leaves and stems of *T. orientalis* are used to treat nervous disorders, insomnia, and heart palpitations, as well as to stop hemorrhages and reduce fever. Recently, the polysaccharide fraction isolated from *T. occidentalis* was reported to demonstrate an anti-human immunodeficiency virus (HIV) activity [7].

*Juniperus oxycedrus* L. ssp. *oxycedrus* was used in folk medicine for the treatment of various infection diseases [8]. *Salvia officinalis* L. is a medicinal plant well-known for its reputation of being a panacea. The inhibitory activity against HSV-1, HSV-2, and an ACV-resistant strain of HSV-1 (ACV (res)) of an aqueous extract of *S. officinalis* was recently reported [9]. The most common *Satureja* specimen is *S. thymbra* L., which is known as an herbal home remedy, due to its antimicrobial, gastrosedative, and diuretic properties [10]. *Pistacia palaestina* Boiss. and *Cupressus sempervirens* ssp. *pyramidalis* L. essential oils have not been investigated so far for their chemical composition and biological activity.

The present study aimed at examining the effects of essential oils obtained from several plants from Lebanon on HSV-1 and SARS-CoV replication *in vitro*.

**Results and Discussion.** – *Compositions of the Oils.* The yields of essential oils ranged from 1.5 to 3.5% (*Table 1*). To identify putative active compounds present within the essential oils, gas-chromatography (GC) systems were employed. The chemical composition of the oils was reported in *Table 2*. *L. nobilis* berry oil was characterized by the presence of β-octimene (21.83%), 1,8-cineole (9.43%), α-pinene (3.67%), and β-pinene (2.14%) as major constituents. Two interesting sesquiterpenes, i.e., eremanthin (3.65%) and dehydrocostus lactone (7.57%), were also identified. *T. orientalis* oil was characterized by 43 constituents (86.68% of the total oil) in which the main components were α-pinene (35.72%), δ-3-carene (9.48%), and α-cedrol (9.55%).

| Plant Location            | Voucher specimen No. | Studied material | % w/w(*) |
|---------------------------|----------------------|------------------|-----------|
| L. nobilis L. Nahr-Ibrahim | 1224                 | Berry            | 3         |
| J. oxycedrus L. ssp. oxycedrus Baskinta | 1267 | Berry | 2.5 |
| T. orientalis L. Ayoun-kourkoush | 1265 | Fruits | 3.5 |
| C. sempervirens L. ssp. pyramidalis Ajaltoun | 1248 | Fruits | 3 |
| P. palaestina Boiss. Ain-Saáde | 1268 | Fruits | 2 |
| S. officinalis L. Ain-Saáde | 1271 | Leaves | 2.25 |
| S. thymbra L. Ayoun-kourkoush | 1273 | Leaves | 1.5 |

*) % w/w: Hydrodistillation yield.
A total of 48 compounds (82.39% of the total oil) were identified in *J. oxycedrus* ssp. *oxycedrus* berry oil. α-Pinene (27.4%) and β-myrcene (18.9%) were the major constituents. Other identified compounds were α-phellandrene (7.1%), limonene (6.7%), epibicyclosesquiphellandrene (2.3%), and δ-cadinene (2.2%). Forty-one components, representing 80.91% of the total, were identified in *S. thymbra* oil, in which *p*-cymene (10.76%), α-pinene (10.15%), thymol (9.92%), sabinene (8.64%), γ-terpinene (7.56%), carvacrol (4.98%), *trans*-caryophyllene (3.67%), β-pinene (2.90%), and linalool (2.81%) were the main abundant compounds.

*C. sempervirens* ssp. *pyramidalis* oil was characterized by 19 components, representing 90.45% of the total oil. The main components were α-pinene (53.56%), α-terpinene (18.90%), thymol (3.84%), and terpinolene (3.15%). Twenty-six compounds were identified in *S. officinalis* (94.39% of the total oil) in which 1,8-cineole (43.62%), α-thujone (12.99%), sabinen (6.97%), camphor (5.71%), α-pinene (4.72%), α-humulene (3.41%), α-terpineol (3.18%), and β-pinene (3.01%) were the major components.

*P. palaestina* oil was characterized by 29 components, representing 79.82% of the total oil. The main components were sabinen (17.08%), limonene (8.56%), β-pinene (6.48%), γ-terpinene (6.33%), *p*-cymene (6.01%), and aromadendrene (3.99%).

**Antiviral Activities.** In this study, we report the antiviral activity of seven essential oils obtained from berry, fruits, and leaves of different species collected in Lebanon. Results are summarized in Table 3. Our results demonstrated how *L. nobilis* berries oil exhibited an *IC*₅₀ value of 120 μg/ml against SARS-CoV with a selectivity index (SI; *TC*₅₀/*IC*₅₀) of 4.2. An interesting activity with an *IC*₅₀ value of 60 μg/ml was found when *L. nobilis* berry oil was incubated with HSV-1 virus. Armaka *et al.* reported the ability...
| Compound | t<sub>0</sub> (s) | Ln<sup>c)</sup> | Joo<sup>c)</sup> | To<sup>c)</sup> | Cp<sup>c)</sup> | Pp<sup>c)</sup> | Sr<sup>c)</sup> | So<sup>c)</sup> | Method<sup>d)</sup> |
|----------|-----------------|-----------------|-----------------|-------------|-------------|-------------|-------------|-------------|-----------------|
| Tricyclic | 6.78 | – | – | 0.28 ± 0.01 | 0.17 ± 0.01 | – | – | 0.10 ± 0.02 | GC/MS |
| α-Thujene | 6.97 | 0.10 ± 0.01 | – | 0.25 ± 0.02 | 0.18 ± 0.01 | 0.92 ± 0.05 | 0.89 ± 0.11 | 0.16 ± 0.01 | GC/MS |
| α-Pinene | 7.13 | 3.67 ± 0.03 | 27.40 ± 0.05 | 35.72 ± 0.63 | 53.56 ± 0.32 | 6.81 ± 0.12 | 10.15 ± 0.32 | 4.72 ± 0.11 | GC/MS |
| α-Fenchene | 7.34 | – | – | 1.21 ± 0.11 | 0.72 ± 0.018 | – | – | – | GC/MS |
| Camphene | 7.38 | 1.69 ± 0.04 | 0.10 ± 0.02 | 0.19 ± 0.04 | 0.24 ± 0.01 | 0.39 ± 0.01 | 0.08 ± 0.009 | 2.55 ± 0.08 | GC/MS |
| m-Cymene | 7.82 | – | – | 0.24 ± 0.02 | – | – | – | – | GC/MS |
| Sabinene | 7.94 | 1.64 ± 0.03 | 4.51 ± 0.01 | 0.85 ± 0.02 | 1.01 ± 0.034 | 17.08 ± 0.25 | 8.64 ± 0.15 | 6.97 ± 0.21 | GC/MS |
| β-Pinen | 7.96 | 2.14 ± 0.01 | 0.40 ± 0.05 | – | 1.78 ± 0.076 | 6.48 ± 0.09 | 2.90 ± 0.18 | 3.01 ± 0.14 | GC/MS |
| β-Myrcene | 8.21 | 0.56 ± 0.01 | 18.90 ± 0.07 | 1.64 ± 0.07 | – | – | 0.68 ± 0.03 | tr | GC/MS |
| α-Phellandrene | 8.49 | 0.11 ± 0.07 | 7.10 ± 0.002 | 0.17 ± 0.01 | – | 1.13 ± 0.03 | tr | – | GC/MS |
| δ-3-Carene | 8.62 | – | – | 9.48 ± 0.12 | – | – | – | – | GC/MS |
| α-Terpinene | 8.71 | 0.15 ± 0.01 | – | 0.15 ± 0.01 | 18.9 ± 0.14 | 3.60 ± 0.06 | 1.10 ± 0.12 | 0.17 ± 0.01 | GC/MS |
| p-Cymene | 8.86 | 0.12 ± 0.05 | 0.51 ± 0.08 | 1.23 ± 0.02 | 0.82 ± 0.02 | 6.01 ± 0.09 | 10.76 ± 0.53 | 1.08 ± 0.04 | GC/MS |
| Limonene | 8.94 | 0.10 ± 0.01 | 6.70 ± 0.05 | 2.90 ± 0.02 | 1.95 ± 0.08 | 8.56 ± 0.11 | 0.57 ± 0.09 | 1.20 ± 0.05 | GC/MS, CoI |
| 1,8-Cineole | 8.98 | 9.43 ± 0.07 | – | – | – | – | 0.28 ± 0.06 | 43.62 ± 0.44 | GC/MS, CoI |
| β-Ocimene | 9.09 | 21.83 ± 0.18 | – | 0.18 ± 0.03 | – | – | – | – | GC/MS |
| α-Ocimene | 9.24 | – | – | 0.12 ± 0.01 | – | – | – | – | GC/MS |
| γ-Terpine | 9.45 | 0.10 ± 0.01 | 0.10 ± 0.01 | 0.87 ± 0.10 | 0.31 ± 0.01 | 6.33 ± 0.12 | 7.56 ± 0.11 | 0.39 ± 0.08 | GC/MS |
| Terpinolene | 9.94 | – | 0.22 ± 0.04 | 2.94 ± 0.22 | 3.15 ± 0.13 | 2.86 ± 0.06 | 0.62 ± 0.15 | tr | GC/MS |
| Fenchone | 9.96 | 0.12 ± 0.02 | – | – | – | – | – | – | GC/MS |
| Linalool | 10.08 | – | 0.40 ± 0.02 | – | – | – | – | 2.81 ± 0.11 | GC/MS, CoI |
| α-Thujone | 10.32 | – | – | – | – | – | 0.08 ± 0.11 | 12.99 ± 0.13 | GC/MS |
| Fenchol | 10.35 | – | – | 0.28 ± 0.01 | – | – | – | – | GC/MS |
| δ-Isothujone | 10.39 | – | – | – | – | – | – | – | GC/MS |
| cis-p-2-Menth-1-ol | 10.45 | – | – | – | – | 0.32 ± 0.05 | – | – | GC/MS |
| α-Campholenaldehyde | 10.52 | – | 0.10 ± 0.06 | 0.22 ± 0.01 | – | – | 0.25 ± 0.11 | – | GC/MS |
| trans-Pinoareveol | 10.74 | – | 0.10 ± 0.03 | 0.57 ± 0.07 | – | – | – | – | GC/MS |
| Camphor | 10.81 | 0.35 ± 0.04 | – | 0.84 ± 0.09 | – | – | – | 5.71 ± 0.12 | GC/MS |
| trans-Pinocamphone | 11.03 | – | – | 0.36 ± 0.01 | – | – | – | – | GC/MS |
| Isopinocamphone | 11.23 | – | – | 0.44 ± 0.01 | – | – | – | – | GC/MS |
Table 2 (cont.)

| Compound a) | \( t R b) \) | \( J_o c) | \( Z_o d) | \( C_p e) | \( P_p f) | \( S_t g) | \( S_o h) | Method \( d) \) |
|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|
| Terpinen-4-ol | 11.28 | – | 0.10 ± 0.05 | – | – | – | – | GC/MS |
| \( \alpha \)-Terpineol | 11.42 | 0.40 ± 0.02 | 0.30 ± 0.08 | 0.20 ± 0.01 | 1.08 ± 0.02 | 2.43 ± 0.08 | 1.53 ± 0.16 | GC/MS, Col |
| Myrtenol | 11.52 | – | – | 0.16 ± 0.03 | – | – | – | GC/MS |
| Isoborneol | 11.58 | 0.31 ± 0.01 | – | 0.15 ± 0.01 | – | – | – | GC/MS |
| cis-Piperitol | 11.65 | – | – | – | – | – | 0.10 ± 0.06 | GC/MS |
| Verbenone | 11.69 | – | 0.10 ± 0.01 | 0.19 ± 0.01 | – | – | – | GC/MS |
| Fenchol acetate | 11.80 | – | – | 0.30 ± 0.02 | – | – | – | GC/MS |
| Isopulegone (1) | 11.82 | – | – | – | – | – | 0.10 ± 0.02 | GC/MS |
| trans-Carveol | 11.93 | – | 0.20 ± 0.03 | – | – | – | – | GC/MS |
| Methyl thymol ether | 12.05 | – | – | – | 0.14 ± 0.01 | 0.38 ± 0.02 | – | GC/MS |
| Pulegone (2) | 12.07 | – | – | – | tr | – | – | GC/MS |
| Citronellol | 12.18 | – | 0.30 ± 0.05 | – | – | – | – | GC/MS |
| Carvone | 12.25 | – | 0.10 ± 0.09 | – | – | – | – | GC/MS |
| Geraniol | 12.32 | – | 0.10 ± 0.02 | – | – | – | tr | GC/MS |
| Neryl acetate | 12.57 | – | – | – | – | 0.26 ± 0.03 | – | GC/MS |
| Bornyl acetate | 12.59 | 0.22 ± 0.01 | 0.62 ± 0.04 | 0.86 ± 0.04 | – | – | – | GC/MS |
| \( \alpha \)-Terpinyl acetate | 12.62 | – | 0.10 ± 0.03 | – | – | – | – | GC/MS |
| Thymol | 12.63 | – | – | 3.84 ± 0.11 | – | 9.92 ± 0.07 | – | GC/MS |
| \( \alpha \)-Fenchyl acetate | 12.65 | – | – | 2.05 ± 0.05 | – | – | – | GC/MS |
| Carvacrol | 12.90 | – | – | – | – | 4.98 ± 0.08 | – | GC/MS |
| Bornylene | 13.19 | – | – | 0.72 ± 0.03 | – | – | – | GC/MS |
| 1-p-Menthen-8-yl acetate | 13.31 | – | – | – | – | 0.40 ± 0.08 | – | GC/MS |
| \( \alpha \)-Cubebeene | 13.35 | – | 0.53 ± 0.07 | – | – | 0.52 ± 0.03 | tr | GC/MS |
| Eugenol | 13.41 | – | – | – | – | – | – | GC/MS |
| \( \alpha \)-Ylangene | 13.67 | 0.22 ± 0.08 | 0.40 ± 0.05 | 0.46 ± 0.02 | – | 0.22 ± 0.01 | – | GC/MS |
| Calarene (3) | 13.69 | – | – | 0.31 ± 0.01 | – | – | – | GC/MS |
| \( \alpha \)-Copaene | 13.71 | 0.17 ± 0.01 | 0.30 ± 0.04 | 0.44 ± 0.01 | – | 0.20 ± 0.01 | 1.67 ± 0.13 | GC/MS |
| \( \alpha \)-Bergamotene | 13.75 | 0.10 ± 0.04 | – | 0.10 ± 0.01 | – | – | – | GC/MS |
| \( \beta \)-Bourbonene (4) | 13.79 | – | – | – | – | 0.24 ± 0.05 | – | GC/MS |
| \( \beta \)-Elemene | 13.81 | 1.0 ± 0.06 | – | – | 0.10 ± 0.01 | 0.21 ± 0.01 | – | GC/MS |
| Methyl eugenol | 13.86 | – | – | – | – | – | – | GC/MS |
| Zingiberene (5) | 13.90 | – | 0.11 ± 0.01 | – | 0.48 ± 0.01 | – | – | GC/MS |
| Compound (g) | tR (min) | ln (°C) | kso (°C) | To (°C) | Csp (°C) | Pp (°C) | St (°C) | So (°C) | Method |
|-------------|----------|---------|----------|---------|----------|---------|--------|--------|--------|
| Longifolene | 13.97    | -       | 0.20 ± 0.02 | -       | -        | -       | -      | -      | GC/MS  |
| Isolongifolene (6) | 14.05 | - | - | - | 1.35 ± 0.02 | - | - | - | GC/MS |
| α-Gurjunene | 14.06 | - | - | - | - | - | 0.51 ± 0.06 | GC/MS |
| trans-Caryophyllene | 14.17 | 0.32 ± 0.04 | 1.00 ± 0.02 | 3.43 ± 0.02 | - | 0.63 ± 0.01 | 3.67 ± 0.11 | 1.05 ± 0.07 | GC/MS, CoI |
| Widdrene (7) | 14.24 | - | 0.81 ± 0.01 | - | - | - | - | - | GC/MS |
| Aromadendrene | 14.30 | - | - | - | - | 3.99 ± 0.01 | - | 0.99 ± 0.04 | GC/MS |
| cis-Thujopsene | 14.32 | - | 0.30 ± 0.02 | - | - | - | - | - | GC/MS |
| β-Gurjunene | 14.36 | - | 0.41 ± 0.01 | - | - | - | - | - | GC/MS |
| trans-β-Farnesene | 14.38 | 0.13 ± 0.01 | 0.32 ± 0.01 | 0.71 ± 0.02 | - | - | - | - | GC/MS |
| α-Humulene | 14.43 | 0.10 ± 0.01 | 1.01 ± 0.05 | 0.42 ± 0.03 | - | 0.29 ± 0.01 | 0.34 ± 0.03 | 3.41 ± 0.45 | GC/MS |
| β-Acoradiene (8) | 14.63 | - | 0.62 ± 0.01 | - | - | - | - | - | GC/MS |
| Epibicyclesquiphellandrene | 14.79 | - | 2.30 ± 0.02 | 1.10 ± 0.07 | - | 2.40 ± 0.03 | 1.68 ± 0.14 | - | GC/MS |
| α-Guaiene | 14.85 | - | - | - | - | - | - | - | GC/MS |
| β-Bisabolene | 14.95 | - | 2.19 ± 0.12 | - | - | - | - | - | GC/MS |
| β-Himachalene | 14.98 | - | 0.89 ± 0.06 | - | - | - | - | - | GC/MS |
| β-Selinene | 15.01 | - | 0.80 ± 0.08 | - | - | - | 0.11 ± 0.02 | - | GC/MS |
| α-Murolene | 15.09 | - | 0.90 ± 0.02 | - | - | - | 0.37 ± 0.04 | - | GC/MS |
| γ-Cadinene | 15.15 | 0.36 ± 0.02 | 0.61 ± 0.07 | - | - | - | - | - | tr GC/MS |
| δ-Cadinene | 15.21 | 0.14 ± 0.01 | 2.20 ± 0.08 | 2.86 ± 0.02 | 0.22 ± 0.01 | 1.51 ± 0.07 | 3.11 ± 0.12 | 0.1 ± 0.01 | GC/MS |
| Cadina-1,4-diene | 15.38 | - | 0.10 ± 0.04 | - | - | - | - | - | GC/MS |
| Palustrol (9) | 15.67 | - | - | - | - | 0.99 ± 0.08 | - | - | GC/MS |
| Spathulenol | 15.73 | - | - | - | - | 0.61 ± 0.07 | - | - | GC/MS |
| γ-Gurjunene | 15.88 | - | - | - | - | 0.31 ± 0.11 | - | 1.16 ± 0.05 | GC/MS |
| Viridiflorol (10) | 15.90 | - | - | - | - | 0.78 ± 0.04 | 0.11 ± 0.04 | - | GC/MS |
| α-Cedrol | 16.03 | - | 0.31 ± 0.05 | 9.55 ± 0.07 | - | - | - | - | GC/MS |
| β-Guaiene | 16.14 | - | - | - | - | 0.16 ± 0.03 | - | - | GC/MS |
| β-Maaliene | 16.44 | - | - | - | - | 3.08 ± 0.04 | - | - | GC/MS |
| Eremophilene | 16.52 | - | 0.20 ± 0.03 | - | - | - | - | - | GC/MS |
| Cadalene (11) | 16.79 | - | 0.10 ± 0.02 | - | - | - | - | - | GC/MS |
| (E,E)-Farnesol | 17.02 | - | 0.60 ± 0.06 | - | - | - | - | - | GC/MS |
| Compound | \( t_R \) | \( Lt \) | \( Joo \) | \( To \) | \( CsP \) | \( Pp \) | \( St \) | \( So \) | Method |
|----------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| 4-Oxo-\( \alpha \)-ylangene | 17.37 | – | – | – | – | – | 0.15 ± 0.07 | – | GC/MS |
| Methyl palmitate | 18.46 | – | 0.10 ± 0.04 | – | – | – | – | – | GC/MS |
| Biformene | 18.64 | – | – | – | – | 0.56 ± 0.01 | 0.10 ± 0.05 | – | GC/MS |
| Palmitic acid | 18.74 | – | 0.21 ± 0.08 | – | – | – | – | – | GC/MS |
| Manoyl oxide | 19.26 | – | 0.20 ± 0.03 | – | – | – | – | – | GC/MS |
| Eremanthin (12) | 19.31 | 3.65 ± 0.09 | – | – | – | – | – | – | GC/MS |
| Rimuene | 19.39 | – | – | – | – | – | 0.71 ± 0.24 | – | GC/MS |
| Ethyl palmitate | 19.56 | – | 0.11 ± 0.07 | – | – | – | – | – | GC/MS |
| Methyl stearate | 19.95 | – | 0.12 ± 0.06 | – | – | – | – | – | GC/MS |
| Ethyl linoleate | 20.29 | – | tr | – | – | – | – | – | GC/MS |
| Ethyl stearate | 20.47 | – | tr | – | – | – | – | – | GC/MS |
| Dehydrocostus lactone (13) | 20.82 | 7.57 ± 0.12 | – | – | – | – | – | – | – |
| Identified compounds | 56.82 | 82.39 | 86.68 | 90.45 | 79.82 | 80.91 | 94.39 |

*) Compounds listed in order of elution from SE30 MS nonpolar column. 1) \( t_R \): Retention time [min]. c) Relative area percentage (peak area relative to total peak area in %). tr: trace, i.e., < 0.05%. 4) CoI: co-injection with authentic compound.
of isoborneol to completely inhibit HSV-1 replication, without affecting viral adsorption [11]. The content of this monoterpene in *L. nobilis* berry oil was found in low percentage, and probably, therefore, it is not able to exert antiviral activity against HSV-1.

A certain activity against SARS-CoV was found for *T. orientalis* and *J. oxycedrus* ssp. *oxycedrus* oils with IC₅₀ values of 130 and 270 µg/ml, and a SI of 3.8 and 3.7, respectively. Interestingly, *J. oxycedrus* ssp. *oxycedrus* oil exhibited the highest activity against HSV-1 with an IC₅₀ value of 200 µg/ml and a SI of 5. On the other hand, *T. orientalis* oil did not show any antiviral activity against HSV-1 when it was incubated under the same conditions. HSV-1 Growth was inhibited also when *S. thymbra* oil was used (IC₅₀ of 220 µg/ml and SI of 4.5). The *C. sempervirens* oil did not exhibit any activity against HSV-1 (IC₅₀ > 1000 µg/ml). This results may be related to the inactivity of the main component α-pinene as we have previously demonstrated [2]. A weak activity against SARS-CoV was found when *C. sempervirens* ssp. *pyramidalis* and *S. officinalis* essential oils were applied in virus culture (IC₅₀ 700 and 870 µg/ml, resp.). *P. palaestina* essential oil was inactive against SARS-CoV (IC₅₀ > 1000 µg/ml) and less active against HSV-1 (IC₅₀ 500 µg/ml). Interestingly, *L. nobilis*, *T. orientalis*, and *J. oxycedrus* ssp. *oxycedrus* oils exhibited higher potencies to inhibit SARS-CoV and a great margin of safety compared to the positive control glycyrrhizin (IC₅₀ 641 µg/ml; SI 1.2).

**Cytotoxic Activity.** Cytotoxic effects of the essential oils were tested in confluent layers of Vero cells by MTT assay. Assessment of cytotoxicity is clearly an important aspect of the evaluation of a potential antiviral agent, because a useful oil should be selective for virus-specific processes with no or only few effects on cellular metabolism. In Vero cells the TC₅₀ value of tested samples was in a range of 120 to 1000 µg/ml.

**Conclusions.** – Severe acute respiratory syndrome (SARS) is an emerging disease that created international anxiety because of its relatively high infectious, rapid

| Essential oil                        | Vero cells | HSV-1 | SARS-CoV |
|--------------------------------------|------------|-------|----------|
|                                      | TC₅₀ [µg/ml] | IC₅₀ [µg/ml] | SI | IC₅₀ [µg/ml] | SI |
| *L. nobilis*                         | 5.0±1.02 | 60±0.5 | 8.3 | 120±1.2 | 4.2 |
| *T. orientalis*                      | >1000 | >1000 | >1 | 130±0.4 | 3.8 |
| *J. oxycedrus* ssp. *oxycedrus*      | 1000±1.7 | 200±1.2 | 5 | 270±1.5 | 3.7 |
| *C. sempervirens* ssp. *pyramidalis*| >1000 | >1000 | >1 | 700±2.3 | 1.5 |
| *P. palaestina*                      | 500±0.8 | 500±2.2 | >1 | >1000 | >1 |
| *S. officinalis*                     | >1000 | >1000 | >1 | 870±1.5 | >1 |
| *S. thymbra*                         | >1000 | 220±1.6 | 4.5 | – | – |
| Acyclovir                            | >22.5 (100 µM) | 0.85 (3.77 µM) | 26.5 | – | – |
| Glycyrrhizin                         | 783.4 (952 µM) | – | – | 641.0 (779 µM) | 1.2 |

*) Results are shown as mean ± SD, n = 3. IC₅₀: concentration required to inhibit 50% of virus growth; TC₅₀: drug concentration that reduces the cell growth by 50% (cellular toxicity); SI = selectivity index (TC₅₀/IC₅₀); –: not tested.
progression and relatively high death rate. The fact that no conventional medicine was used for the treatment of SARS was based on the evidence that natural products from plants exhibited antiviral activity to other coronaviruses although the mechanism of action of these herbal products is mainly through inhibition of viral replication [12].

In this paper, we presented the first evidence for a strong antiviral activity of *L. nobilis* oil against SARS-CoV, and we also reported the interesting anti-herpetic activity of *J. oxycedrus* ssp. *oxycedrus* and *S. thymbra* oils providing a potential use of these oils for treatment of viral infectious diseases.

**Experimental Part**

**Plant Materials.** Berries of *Laurus nobilis* L. (Lauraceae) and *Juniperus oxycedrus* L. ssp. *oxycedrus* (Cupressaceae), fruits of *Thuja orientalis* L. (Cupressaceae), *Cupressus sempervirens* L. ssp. *pyramidalis* (Cupressaceae), and *Pistacia palaestina* Boiss. (Labiatae), *Salvia officinalis* L. (Labiatae), and leaves of *Satureja thymbra* L. (Labiatae) were collected from June to November 2003 in Lebanon (*Table 1*). A voucher specimen of each plant was authenticated botanically by Prof. S. Safi, Biology Department, Faculty of Sciences II, Lebanese University, and deposited with the Herbarium of Faculty of Sciences II, Lebanese University.

**Isolation of Essential Oils.** The fresh aerial parts (200 g of each of the above mentioned species) were submitted to hydrodistillation for 3 h using a Clevenger-type apparatus as described in [2], yields in percent are listed in *Table 1*. The white-yellow essential oils were dried (anh. Na2SO4) to remove traces of moisture and stored at 4–8 °C in bottles covered with aluminium foil to prevent the negative effect of light.

**GC/MS Analysis.** To determine the essential oils composition, analyses were carried out using a GC system (Hewlett-Packard Co., model 6890) with a fused cap. column (30 m length; 0.25 mm i.d.; 0.25-μm film thickness; static phase methylsilicone SE-30) directly coupled to a selective mass detector (Hewlett Packard 5973). Electron impact ionization was carried out at an energy of 70 eV. He was used as carrier gas. Injector and detector were maintained at 250 and 280 °C, resp. The anal. conditions were as follows: oven temp. was 5 min isothermal at 60 °C. Then 60–280 °C at a rate of 16 °C/min, then held isothermal for 10 min. The mass range from 50 to 550 amu was scanned at a rate of 2.9 scans/s. Identification of the components was based on the comparison of the MS data on computer matching against *Wiley 138* and those described in literature (*Table 2*) [13].

**Cytotoxicity Assay.** Cytotoxicity of the essential oils towards Vero cells was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) dye reduction in active mitochondria using monkey kidney cell line Vero (*ATCC*, Manassas, VA) as described in [2]. The drug concentration that reduced the cell growth by 50% is expressed as TC50 (Tissue Culture 50).

**Antiviral Assay.** Antiviral action of essential oils against HSV (F Strain ATCC VR733) and SARS-CoV (isolate FFM-1 obtained from the sputum of a patient hospitalized with a diagnosis of SARS in the Isolation Unit of Frankfurt University Hospital, Germany) replication was tested as follows. Vero cells were seeded in 96-well plates and infected with HSV-1 or SARS-CoV at multiplicity of infection (MOI) of 0.01. The viruses were propagated in Vero cells as described in [2][14]. In accordance with WHO recommendations, all work involving infectious SARS-CoV was performed under biosafety level (BSL)-3 conditions in a BSL-3 facility. Acyclovir (ACV) was used as a control for antiviral activity against HSV-1, while glycyrrhizin (GLZ) was used against SARS-CoV. Both positive control compounds were purchased from Sigma-Aldrich, D-Munich. Virus and the tested essential oils of different concentrations were added at the same time in MEM supplemented with 2% FBS. For each dilution step, 8 wells were used in parallel. Virus infection was assessed by visually scoring of the virus-induced cytopathogenic effect (CPE) 72 h (HSV-1) or 48 h (SARS-CoV) post-infection. The effective concentration inhibiting 50% of virus growth (*IC*50) was determined as concentration of compound required to inhibit the CPE effect to 50% of the control value. The selective index (SI), also known as a therapeutic ratio or margin of safety, is the ratio of the amount of drug that causes a therapeutic effect to the amount that causes a toxic effect, *i.e.*, TC50/IC50.
REFERENCES

[1] M. T.H. Khan, A. Ather, K. D. Thompson, A. Gambari, *Antiviral Res.* 2005, 67, 107.
[2] M. R. Loizzo, A. Saab, R. Tundis, G. A. Statti, I. Lampronti, F. Menichini, G. Gambari, J. Cinatl, H. W. Doerr, *Phytomedicine* 2007, in press.
[3] J. S. Peiris, Y. Guan, K. Y. Yuen, *Nat. Med.* 2004, 10, S88.
[4] D. M. Coen, *Adv. Exp. Med. Biol.* 1996, 394, 49.
[5] M. E. Ernst, R. J. Francy, *Ann. Pharmacother.* 1998, 32, 111.
[6] B. Hafizoglu, M. Reunanen, *Fat Sci. Technol.* 1993, 95, 304.
[7] H. T. Hassan, N. J. Drize, E. Yu. Sadovinkova, O. I. Gan, S. Gohla, R. D. Neth, *Immunol. Lett.* 1996, 50, 119.
[8] I. Karaman, E. Sahin, M. Gulluce, H. Ongutcu, A. Sengul Adguzel, *J. Ethnopharmacol.* 2003, 85, 231.
[9] S. Nolkemper, J. Reichling, F. C. Stintzing, R. Carle, P. Schnitzler, *Planta Med.* 2006, 72, 1378.
[10] N. Chorianopoulos, E. Kalpoutzakis, N. Aligiannis, S. Mitaku, G. J. E. Nychas, S. A. Haroutounian, *J. Agric. Food Chem.* 2004, 52, 8261.
[11] M. Armaka, E. Papanikolaou, A. Sivropoulou, M. Arsenakis, *Antiviral Res.* 1999, 43, 79.
[12] A. R. McCutcheon, T. E. Roberts, E. Gibbons, S. M. Ellis, L. A. Babiuk, R. E. Hancock, G. H. Towers, *J. Ethnopharmacol.* 1995, 49, 101.
[13] R. Adams, ‘Identification of Essential Oil Components by Gas Chromatography/Mass Spectroscopy’, Allured Publishing Co., Carol Stream, 1995.
[14] H. F. Rabenau, G. Kampf, J. Cinatl, H. W. Doerr, *J. Hosp. Infect.* 2005, 61, 107.

Received June 15, 2007